Science and Technology

Archive | news

February 13, 2014

X-Chem Licenses Epigenetic Drug Discovery Program to Bayer Pharma AG

WALTHAM, Mass. – February 13, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved a success milestone with Bayer Pharma AG in the multi-target collaboration the companies established in July 2012.

Continue Reading
February 2, 2014

X-Chem First Biotech to Exceed 100 Billion Compounds with its Unique and Proprietary Small Molecule DNA-Encoded Library

WALTHAM, MA, USA – February 4, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its powerful product engine to the generation of novel small molecule therapeutics, today announced that the company has created the first biotech-owned screening library of DNA-encoded small molecules to ever surpass 100 billion compounds.

Continue Reading
October 3, 2013

X-Chem Enters Expanded Global Drug Discovery Collaboration with AstraZeneca

WALTHAM, Mass. – October 3, 2013 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company’s therapeutic areas and multiple target […]

Continue Reading
September 23, 2013

X-Chem Achieves Early Success in Collaboration with AstraZeneca, Licenses Three Drug Discovery Programs

WALTHAM, Mass. – September 24, 2013 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has achieved several milestones leading to the licensing of three drug discovery programs by AstraZeneca, in the context of a collaboration the […]

Continue Reading